News - Adasuve, ISTA Pharmaceutical


Popular Filters

Planned expansion of anti-psychotic drug throughout Europe


Austrian drugmaker AOP Orphan and privately held Spanish drugmaker Ferrer Internacional are expanding…

AdasuveAOP OrphanEuropeFerrer InternacionalMarkets & MarketingNeurologicalPharmaceutical

Ferrer and Medivir join forces on Adasuve for Nordic markets


Sweden’s Medivir (Nasdaq OMX: MVIR) and privately-held Spanish drugmaker Ferrer Internacional have…

AdasuveAlexza PharmaceuticalEuropeFerrer InternacionalLicensingMedivirNeurologicalPharmaceutical

Alexza deal with Teva sets stage for Adasuve, say analysts


USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical…

AdasuveAlexza PharmaceuticalAZ-002FinancialLicensingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

FDA sets PDUFA date for Alexza's resubmission for Adasuve


Following two earlier rejections, the US Food and Drug Administration has now accepted Alexza Pharmaceuticals…

AdasuveAlexza PharmaceuticalFerrer InternacionalNeurologicalNorth AmericaPharmaceuticalRegulation

Alexza rockets on re-submission of Adasuve NDA


USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) saw its shares soar 44.9% to close at $3.97 on Friday,…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies


California, USA-based Alexza Pharmaceuticals (Nasdaq: ALXA) revealed last week that it has received another…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

ISTA Pharma accepts $500 million bid from Bausch & Lomb; settles royalty dispute


US ophthalmic drugmaker ISTA Pharmaceuticals (Nasdaq: ISTA), which rejected a hostile takeover bid from…

Bausch & LombBromdayISTA PharmaceuticalLicensingMergers & AcquisitionsOphthalmicsPharmaceuticalProlensaSenju PharmaceuticalXibrom

Valeant pulls out of deal with ISTA, which announces Beposone progress


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says that it has withdrawn…

BeposoneISTA PharmaceuticalMergers & AcquisitionsOphthalmicsPharmaceuticalResearchRespiratory and PulmonaryValeant Pharmaceuticals

PDUFA goal date for Alexza’s Adasuve extended, as Public Citizen says drug should not be approved


US drug firm Alexza Pharmaceuticals (Nasdaq: ALXA) says that the US Food and Drug Administration will…

AdasuveAlexza PharmaceuticalNeurologicalNorth AmericaPharmaceuticalRegulation

Valeant ups its bid for ISTA Pharma


California, USA-based ophthalmology and allergy drug company ISTA Pharmaceuticals (Nasdaq: ISTA) says…

ISTA PharmaceuticalMergers & AcquisitionsOphthalmicsPharmaceuticalRespiratory and PulmonaryValeant Pharmaceuticals

ISTA Pharma rejects Valeant’s advances; Alexza could be for sale


Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) has entered into another…

AdasuveAlexza PharmaceuticalISTA PharmaceuticalMergers & AcquisitionsNeurologicalOphthalmicsPharmaceuticalValeant Pharmaceuticals

FDA advisory panel backs Alexza antipsychotic drug


The US Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee (PDAC) has voted…

AdasuveAlexza PharmaceuticalFinancialLoxapineNeurologicalPharmaceuticalRegulation

Company Spotlight



Back to top